An observational study in Pharmacokinetics and Critical Illness, sponsored by Universitaire Ziekenhuizen KU Leuven. Completed at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-28.
Sponsored by Universitaire Ziekenhuizen KU Leuven · Observational
WP2.1. PK/PD target attainment Plasma exposure ELF exposure WP2.2. Predictive dosing algorithm WP2.3. ECMO subset
First, the investigators will document exposure to ceftriaxone in plasma and epithelial lining fluid.
Second, the investigators will try to identify risk factors for not attaining PK/PD target. Based on significant predictors for target non attainment a predictive dosing algorithm will be constructed.
Finally in a small subset of ECMO patients PK exposure will be explored.
41 studies on the registry are indexed under Hypoalbuminemia; 9 are open to participants now.
This study's enrollment of 30 is below the median of 160 across 15 observational studies indexed under Hypoalbuminemia.
Browse Hypoalbuminemia studies →Universitaire Ziekenhuizen KU Leuven is the lead sponsor of 963 studies on the registry; 267 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Compared within Hypoalbuminemia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Critical Illness. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Critically ill patients receiving ceftriaxone treatment for pneumonia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Risk factors for target non attainment
risk factors will be assessed by comparing patients who attain target vs. those who don't
Time frame: on day of sampling
Plan to share: Undecided — To be discussed
No publications or documents are linked to this record.
Ran from Jan 2013 to primary completion in Feb 2018, 61 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universitaire Ziekenhuizen KU Leuven →